Radiopharmaceutical Shows Promise for Lung Cancer Brain Metastases
A small Chinese study found Lu-177 FAP-2286 shrank brain tumors in most advanced lung cancer patients treated.
Updated on Nov. 4, 2026 in Cancer
Researchers in China evaluated Lu-177 FAP-2286 radiopharmaceutical therapy in 14 patients with advanced lung cancer and brain metastases who had failed prior treatments. The study, published in Scientific Reports on November 3, 2026, reported intracranial responses in most participants.
Why it matters
Brain metastases are difficult to treat, and the findings suggest a targeted radiopharmaceutical approach could offer a new option for patients with limited alternatives. Because the sample was small and uncontrolled, the researchers called for larger randomized trials before any change in standard care.
In a study of 14 patients who had failed at least one prior line of therapy, 57.1% achieved an intracranial objective response and 92.9% achieved disease control. The study had no comparison group, and whether these responses translate to larger populations remains untested.
The players
Scientific Reports
An open-access peer-reviewed journal published by Nature Portfolio that covers natural sciences and medicine.
The details
Patients with confirmed brain metastases received Lu-177 FAP-2286 at 7.4 GBq per cycle, averaging 3.1 cycles each. The therapy targets fibroblast activation protein, which is overexpressed on cancer-associated fibroblasts in brain lesions while showing negligible expression in normal brain tissue.
Timeline
- November 3, 2026: Study published in Scientific Reports
Big Picture
FAP-targeted radiopharmaceuticals have been studied mainly in extracranial tumors, and this small study extends that research into brain metastases from lung cancer. Its results are preliminary and will need confirmation in controlled trials before the approach is adopted in routine care.
For patients with lung cancer that has spread to the brain, this approach is still experimental and is not available as standard treatment. Anyone considering it should discuss clinical trial options and established brain-directed therapies with their oncology team.
The takeaway
Early results for new radiopharmaceuticals in brain metastases are encouraging, but controlled trials are needed before they change treatment decisions for patients.
Further reading
Explore more on Cancer treatment research and emerging therapies.
Source note: This article includes information reported by AuntMinnie.
